SIRT6蛋白在肝脏能量稳态中的调控作用

摘要/Abstract

摘要： SIRT6是Sirtuin家族成员,具有烟酰胺腺嘌呤二核苷酸依赖的组蛋白去乙酰化酶活性和单ADP-核糖基转移酶活性。以前的研究重点是SIRT6蛋白去乙酰化酶活性,随着研究的深入,SIRT6作为影响非酒精性脂肪肝、非酒精性脂肪性肝炎、肥胖和2型糖尿病的相关因子,引起越来越多的关注,尤其SIRT6对肝脏代谢能量稳态、抗氧化应激反应的研究已有一定进展。本文将重点综述SIRT6对肝脏糖代谢、脂质代谢、蛋白质合成及抗氧化应激中的调控作用。

程义尧, 韩小娟, 徐文静. SIRT6蛋白在肝脏能量稳态中的调控作用[J]. 肝脏, 2023, 28(4): 496-499.

参考文献

[1] Buzzetti E, Pinzani M, Tsochatzis E A. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism, 2016, 65(8): 1038-1048.
[2] Chang A R, Ferrer C M, Mostoslavsky R. SIRT6, a mammalian deacylase with multitasking abilities. Physiol Rev, 2020, 100(1): 145-169.
[3] D'onofrio N, Servillo L, Balestrieri M L. SIRT1 and SIRT6 signaling pathways in cardiovascular disease protection. Antioxid Redox Signal, 2018, 28(8): 711-732.
[4] Saisho Y. Beta-cell dysfunction: Its critical role in prevention and management of type 2 diabetes. World J Diabetes, 2015, 6(1): 109-24.
[5] Mostoslavsky R, Chua Kf Fau- Lombard D B, Lombard Db Fau-Pang W W, et al. Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell,2006, 124(2):315-329.
[6] Xiao C, Kim Hs Fau-Lahusen T, Lahusen T Fau-Wang R-H, et al. SIRT6 deficiency results in severe hypoglycemia by enhancing both basal and insulin-stimulated glucose uptake in mice,The Journal of Biological Chemistry,2010,285(47):36776-84.
[7] Sociali G, Magnone M, Ravera S, et al. Pharmacological SIRT6 inhibition improves glucose tolerance in a type 2 diabetes mouse model.FASEB Journal,2017,31(7):3138-3149.
[8] Song M Y, Wang J, Ka S O, et al. Insulin secretion impairment in Sirt6 knockout pancreatic beta cells is mediated by suppression of the FoxO1-Pdx1-Glut2 pathway. Sci Rep, 2016, 6: 30321.
[9] Yang S J, Choi J M, Chae S W, et al. Activation of peroxisome proliferator-activated receptor gamma by rosiglitazone increases sirt6 expression and ameliorates hepatic steatosis in rats. PLoS One, 2011, 6(2): e17057.
[10] Xiong X, Wang G, Tao R, et al. Sirtuin 6 regulates glucose-stimulated insulin secretion in mouse pancreatic beta cells. Diabetologia, 2016, 59(1): 151-160.
[11] Xiong X, Sun X, Wang Q, et al. SIRT6 protects against palmitate-induced pancreatic beta-cell dysfunction and apoptosis. J Endocrinol, 2016, 231(2): 159-165.
[12] Bae E J. Sirtuin 6, a possible therapeutic target for type 2 diabetes. Arch Pharm Res,2017,40(12):1380-1389.
[13] Fan Y, Yang Q, Yang Y, et al. SIRT6 suppresses high glucose-induced mitochondrial dysfunction and apoptosis in podocytes through AMPK activation. Int J Biol Sci, 2019, 15(3): 701-713.
[14] Dong X C. FOXO transcription factors in non-alcoholic fatty liver disease. Liver Res, 2017, 1(3): 168-173.
[15] Roichman A a-O, Elhanati S, Aon M A, et al. Restoration of energy homeostasis by SIRT6 extends healthy lifespan.Nature communications,2021,12(1):3208-3215.
[16] Zhang P, Tu B, Wang H, et al. Tumor suppressor p53 cooperates with SIRT6 to regulate gluconeogenesis by promoting FoxO1 nuclear exclusion. Proc Natl Acad Sci USA, 2014, 111(29): 10684-106899.
[17] Kuang J, Chen L, Tang Q, et al. The Role of SIRT6 in obesity and diabetes. Front Physiol, 2018, 9: 135-144.
[18] Kuang J, Zhang Y, Liu Q, et al. Fat-specific SIRT6 ablation sensitizes mice to high-fat diet-induced obesity and insulin resistance by inhibiting lipolysis. Diabetes, 2017, 66(5): 1159-1171.
[19] Naiman S, Huynh F K, Gil R, et al. SIRT6 promotes hepatic beta-oxidation via activation of PPARα. Cell Rep, 2019, 29(12): 4127-4143.e8.
[20] Dixon E D, Nardo A D, Claudel T, et al. The role of lipid sensing nuclear receptors (PPARs and LXR) and metabolic lipases in obesity, diabetes and NAFLD. Genes (Basel), 2021, 12(5)645-652.
[21] Zhu C, Huang M, Kim H G, et al. SIRT6 controls hepatic lipogenesis by suppressing LXR, ChREBP, and SREBP1. Biochim Biophys Acta Mol Basis Dis, 2021, 1867(12): 166249.
[22] Martinez-Jimenez V, Cortez-Espinosa N, Rodriguez-Varela E, et al. Altered levels of sirtuin genes (SIRT1, SIRT2, SIRT3 and SIRT6) and their target genes in adipose tissue from individual with obesity. Diabetes Metab Syndr, 2019, 13(1): 582-589.
[23] Chen L, Liu Q, Tang Q, et al. Hepatocyte-specific Sirt6 deficiency impairs ketogenesis. J Biol Chem, 2019, 294(5): 1579-1589.
[24] Maiers J L, Malhi H. Endoplasmic reticulum stress in metabolic liver diseases and hepatic fibrosis.Seminars in Liver Disease.2019;39(2):235-248.
[25] Bang IH, Kwon OK, Hao L, et al. Deacetylation of XBP1s by sirtuin 6 confers resistance to ER stress-induced hepatic steatosis. Exp Mol Med, 2019, 51(9): 1-11.
[26] Ravi V, Jain A, Khan D, et al. SIRT6 transcriptionally regulates global protein synthesis through transcription factor Sp1 independent of its deacetylase activity.Nucleic Acids Research,2019,47(17):9115-9131.
[27] Yao L, Cui X, Chen Q, et al. Cold-inducible SIRT6 regulates thermogenesis of brown and beige fat. Cell Rep, 2017, 20(3): 641-654.
[28] Pan H, Guan D, Liu X, et al. SIRT6 safeguards human mesenchymal stem cells from oxidative stress by coactivating NRF2.Cell Research,2016,6(2):190-205.
[29] Kim H G, Huang M, Xin Y, et al. The epigenetic regulator SIRT6 protects the liver from alcohol-induced tissue injury by reducing oxidative stress in mice. J Hepatol, 2019, 71(5): 960-969.
[30] Ka S O, Bang I H, Bae E J, et al. Hepatocyte-specific sirtuin 6 deletion predisposes to nonalcoholic steatohepatitis by up-regulation of Bach1, an Nrf2 repressor.FASEB Journal,2017,31(9):3999-4010.